Eptinezumab: clinical trials recruiting now
4
Recruiting trials
8
Conditions studied
16
US states with sites
12
Countries
FDA drug label
- FDA-approved
- Yes. Eptinezumab appears in the FDA drug-label database. Marketed as Vyepti.
- Drug class
- Calcitonin Gene-related Peptide Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Calcitonin Gene-related Peptide Antagonists (as stated on the FDA label)
FDA-approved use
VYEPTI is indicated for the preventive treatment of migraine in adults. VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults ( 1 )
Phase breakdown
Phase 3 3
Not applicable 1
Conditions being studied
Recruiting trials involving Eptinezumab
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- China HeadAche DIsorders RegiStry
Common questions
Is Eptinezumab FDA-approved?
Yes, marketed as Vyepti.
How many recruiting trials involve Eptinezumab?
4 recruiting trials across 8 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.